Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of Renal Tumor Antigen Is Associated with Tumor Invasion and Poor Prognosis of Hepatocellular Carcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 12 October 2011

Abstract

Purpose

The aim of this study was to investigate the roles of renal tumor antigen (RAGE) in the progression and clinical outcome of hepatocellular carcinoma (HCC).

Methods

RAGE mRNA levels in 350 cases of HCC were investigated by quantitative real-time reverse transcription polymerase chain reaction. We analyzed the relationship of RAGE mRNA level with clinicopathologic parameters and clinical outcome. To identify the possible role of RAGE on cellular invasion, we performed in vitro analyses using small interfering RNAs (siRNAs).

Results

RAGE mRNA level was significantly higher in HCC than in noncancerous hepatic tissues (P < 0.001). Overexpression of RAGE was significantly correlated with the presence of multiple tumors (P = 0.021), high alfa-fetoprotein level (P = 0.042), and advanced tumor stage (P = 0.016). Higher levels of RAGE expression were associated with significantly shorter overall survival time (P = 0.029). Knockdown of RAGE expression by siRNAs suppressed the invasive ability of HCC cells and the expression and secretion of matrix metalloproteinase-9 (MMP-9). We found that RAGE and MMP-9 expressions were correlated in HCCs, and furthermore, the combination of RAGE and MMP-9 expression was associated with the survival of patients (P = 0.0066).

Conclusions

Our results suggest that RAGE may be important in tumor invasion and could be a potential predictor for the prognosis of HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16.

    Article  PubMed  Google Scholar 

  3. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11:790–800.

    Article  PubMed  CAS  Google Scholar 

  4. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.

    Article  PubMed  CAS  Google Scholar 

  5. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.

    Article  PubMed  Google Scholar 

  6. Gaugler B, Brouwenstijn N, Vantomme V, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 1996;44:323–30.

    Article  PubMed  CAS  Google Scholar 

  7. Miyata Y, Akashi M, Nishida E. Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells. 1999;4:299–309.

    Article  PubMed  CAS  Google Scholar 

  8. Oehlrich N, Devitt G, Linnebacher M, et al. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005;117:256–64.

    Article  PubMed  CAS  Google Scholar 

  9. Guinn BA, Gilkes AF, Woodward E, et al. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochem Biophys Res Commun. 2005;333:703–13.

    Article  PubMed  CAS  Google Scholar 

  10. Sigalotti L, Coral S, Altomonte M, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002;86:979–82.

    Article  PubMed  CAS  Google Scholar 

  11. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.

    Article  PubMed  CAS  Google Scholar 

  12. Kim J, Hong SJ, Lim EK, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 2009;28:20.

    Article  PubMed  CAS  Google Scholar 

  13. Kwon JH, Kim J, Park JY, et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res. 2010;16:5511–21.

    Article  PubMed  CAS  Google Scholar 

  14. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.

    Google Scholar 

  15. Kim DG, Park SY, Kim H, Chun YH, Moon WS, Park SH. A comprehensive karyotypic analysis on a newly established sarcomatoid hepatocellular carcinoma cell line SH-J1 by comparative genomic hybridization and chromosome painting. Cancer Genet Cytogenet. 2002;132:120–4.

    Article  PubMed  CAS  Google Scholar 

  16. Lee D, Kwon JH, Kim EH, Kim ES, Choi KY. HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus—positive HeLa cells. Cancer Lett. 2010;292:125–32.

    Article  PubMed  CAS  Google Scholar 

  17. Park HS, Kim KR, Lee HJ, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep. 2007;18:1435–41.

    PubMed  CAS  Google Scholar 

  18. Cokakli M, Erdal E, Nart D, et al. Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer. 2009;9:65.

    Article  PubMed  Google Scholar 

  19. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979–92.

    Article  PubMed  CAS  Google Scholar 

  20. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004;130:497–513.

    Article  PubMed  CAS  Google Scholar 

  21. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112:44–50.

    Article  PubMed  CAS  Google Scholar 

  22. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.

    Article  PubMed  CAS  Google Scholar 

  23. Tang ZY, Ye SL, Liu YK, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.

    Article  PubMed  Google Scholar 

  24. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182–8.

    Article  PubMed  Google Scholar 

  25. Theret N, Musso O, Turlin B, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology. 2001;34:82–8.

    Article  PubMed  CAS  Google Scholar 

  26. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375–82.

    Article  PubMed  Google Scholar 

  27. Shirabe K, Kajiyama K, Harimoto N, et al. Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion. World J Gastroenterol. 2009;15:2632–7.

    Article  PubMed  Google Scholar 

  28. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002;37:375–536.

    Article  PubMed  Google Scholar 

  29. Arii S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology. 1996;24:316–22.

    Article  PubMed  CAS  Google Scholar 

  30. Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kilic M. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2010;16:621–30.

    PubMed  Google Scholar 

  31. Hayasaka A, Suzuki N, Fujimoto N, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology. 1996;24:1058–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This research was financially supported by the Ministry of Education, Science and Technology and Korea Institute for Advancement of Technology through the Human Resource Training Project for Regional Innovation and by grant 10024733 of the Ministry of Knowledge and Economy of Korea. We thank Dr. D.-G. Kim for providing SH-J1 cells.

Author information

Authors and Affiliations

  1. Department of Life Science, Pohang University of Science and Technology, Pohang, Korea

    Hyung Jin Cha BS, Sun Mi Hong BS & Kwan Yong Choi PhD

  2. Cbs Bioscience Inc., Daejeon, Korea

    Jongmin Kim PhD, Seok Joo Hong PhD & Jun Ho Park BS

  3. School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology, Pohang, Korea

    Eung-Sam Kim MS & Kwan Yong Choi PhD

  4. Department of Surgery, Ajou University School of Medicine, Suwon, Korea

    Hee-Jung Wang MD

  5. Department of Pathology, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi, Korea

    Yoon Jung Choi MD

  6. Experimental Pathology Center, Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea

    In-Gu Do MD

  7. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Jae Won Joh MD

  8. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    Dae Shick Kim MD, PhD

Authors
  1. Hyung Jin Cha BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jongmin Kim PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sun Mi Hong BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seok Joo Hong PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Ho Park BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eung-Sam Kim MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hee-Jung Wang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoon Jung Choi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. In-Gu Do MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jae Won Joh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dae Shick Kim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kwan Yong Choi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kwan Yong Choi PhD.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cha, H.J., Kim, J., Hong, S.M. et al. Overexpression of Renal Tumor Antigen Is Associated with Tumor Invasion and Poor Prognosis of Hepatocellular Carcinoma. Ann Surg Oncol 19 (Suppl 3), 404–411 (2012). https://doi.org/10.1245/s10434-011-1856-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1856-3

Keywords

Search

Navigation